Gary Landreth

Summary

Affiliation: Case Western Reserve University
Country: USA

Publications

  1. pmc PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease
    Gary Landreth
    Alzheimer Research Laboratory, Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
    Neurotherapeutics 5:481-9. 2008
  2. pmc In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis
    JASON D ULRICH
    Department of Neurology, Saint Louis, MO, USA
    Mol Neurodegener 8:13. 2013
  3. pmc Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"
    Gary E Landreth
    Alzheimer Research Laboratory, Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
    Science 340:924-g. 2013
  4. pmc Toll-like receptors in Alzheimer's disease
    Gary E Landreth
    Alzheimer Research Laboratory, Department of Neurosciences, Case Western Reserve University, Cleveland, OH 44106, USA
    Curr Top Microbiol Immunol 336:137-53. 2009
  5. ncbi request reprint PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease
    Gary Landreth
    Department of Neurosciences, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA
    Exp Neurol 199:245-8. 2006
  6. ncbi request reprint Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease
    Gary Landreth
    Department of Neurosciences, Case Western Reserve University, School of Medicine, 10900 Euclid Ave, Cleveland, OH 44106, USA
    Curr Alzheimer Res 4:159-64. 2007
  7. ncbi request reprint The immunology of Alzheimer's disease: prospects towards harnessing disease mechanisms for therapeutic ends
    Gary Landreth
    Department of Neurosciences, Case Western Reserve University, Cleveland, OH 44106, USA
    J Neuroimmune Pharmacol 2:131-3. 2007
  8. ncbi request reprint PPARgamma as a therapeutic target in central nervous system diseases
    Sophia Sundararajan
    Department of Neurology, Case Western Reserve University, Cleveland, OH 44106 4928, United States
    Neurochem Int 49:136-44. 2006
  9. pmc The CD40-autophagy pathway is needed for host protection despite IFN-Γ-dependent immunity and CD40 induces autophagy via control of P21 levels
    Jose Andres C Portillo
    Department of Ophthalmology and Visual Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America
    PLoS ONE 5:e14472. 2010
  10. ncbi request reprint Statins reduce amyloid-beta production through inhibition of protein isoprenylation
    Stephen M Ostrowski
    Department of Neurosciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA
    J Biol Chem 282:26832-44. 2007

Research Grants

Collaborators

Detail Information

Publications15

  1. pmc PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease
    Gary Landreth
    Alzheimer Research Laboratory, Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
    Neurotherapeutics 5:481-9. 2008
    ..Recent clinical trials of the PPARgamma agonist rosiglitazone have shown significant improvement in memory and cognition in AD patients. Thus, PPARgamma represents an important new therapeutic target in treating AD...
  2. pmc In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis
    JASON D ULRICH
    Department of Neurology, Saint Louis, MO, USA
    Mol Neurodegener 8:13. 2013
    ..We have developed an assay to measure apoE levels in the brain interstitial fluid of awake and freely moving mice using large molecular weight cut-off microdialysis probes...
  3. pmc Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"
    Gary E Landreth
    Alzheimer Research Laboratory, Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
    Science 340:924-g. 2013
    ..However, we concluded that plaque burden is functionally unrelated to improved cognition and memory elicited by bexarotene...
  4. pmc Toll-like receptors in Alzheimer's disease
    Gary E Landreth
    Alzheimer Research Laboratory, Department of Neurosciences, Case Western Reserve University, Cleveland, OH 44106, USA
    Curr Top Microbiol Immunol 336:137-53. 2009
    ..The TLR-mediated microglial response has beneficial roles in stimulating phagocytosis as well as detrimental roles in the Abeta-stimulated release of neurotoxic products...
  5. ncbi request reprint PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease
    Gary Landreth
    Department of Neurosciences, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA
    Exp Neurol 199:245-8. 2006
  6. ncbi request reprint Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease
    Gary Landreth
    Department of Neurosciences, Case Western Reserve University, School of Medicine, 10900 Euclid Ave, Cleveland, OH 44106, USA
    Curr Alzheimer Res 4:159-64. 2007
    ..Importantly, recent clinical trials of FDA approved PPARgamma agonists have been shown to improve cognition and memory in AD patients. Thus, PPARgamma agonists represent a new and potentially efficacious treatment of AD...
  7. ncbi request reprint The immunology of Alzheimer's disease: prospects towards harnessing disease mechanisms for therapeutic ends
    Gary Landreth
    Department of Neurosciences, Case Western Reserve University, Cleveland, OH 44106, USA
    J Neuroimmune Pharmacol 2:131-3. 2007
  8. ncbi request reprint PPARgamma as a therapeutic target in central nervous system diseases
    Sophia Sundararajan
    Department of Neurology, Case Western Reserve University, Cleveland, OH 44106 4928, United States
    Neurochem Int 49:136-44. 2006
    ..The availability of FDA-approved agonists of this receptor will facilitate the rapid translation of these findings into clinical trials for a number of CNS diseases...
  9. pmc The CD40-autophagy pathway is needed for host protection despite IFN-Γ-dependent immunity and CD40 induces autophagy via control of P21 levels
    Jose Andres C Portillo
    Department of Ophthalmology and Visual Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America
    PLoS ONE 5:e14472. 2010
    ..In addition, they support that autophagy is a mechanism through which CD40-dependent immunity mediates in vivo protection and that the CD40-autophagic machinery is needed for host resistance despite IFN-γ...
  10. ncbi request reprint Statins reduce amyloid-beta production through inhibition of protein isoprenylation
    Stephen M Ostrowski
    Department of Neurosciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA
    J Biol Chem 282:26832-44. 2007
    ..These studies provide insight into the mechanisms by which statins may reduce AD pathogenesis...
  11. ncbi request reprint Mechanisms of statin-mediated inhibition of small G-protein function
    Andrew Cordle
    Department of Neuroscience, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
    J Biol Chem 280:34202-9. 2005
    ..These results suggest a mechanism by which statins inhibit the actions of Rho GTPases and attenuate Abeta-stimulated inflammation...
  12. pmc Nuclear receptors as therapeutic targets for Alzheimer's disease
    Shweta Mandrekar-Colucci
    Case Western Reserve University School of Medicine, Department of Neurosciences, Alzheimer Research Laboratory, Cleveland, OH 44106, USA
    Expert Opin Ther Targets 15:1085-97. 2011
    ..This accumulation of amyloid is associated with perturbations in synaptic function, impairments in energy metabolism and induction of a chronic inflammatory response which acts to promote neuronal loss and cognitive impairment...
  13. pmc Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma
    Magdalena Sastre
    Department of Neurology, University of Bonn, Sigmund Freud Strasse 25, 53127 Bonn, Germany
    Proc Natl Acad Sci U S A 103:443-8. 2006
    ....
  14. ncbi request reprint Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease
    Qiao Yan
    Department of Neuroscience, Amgen Inc, Thousand Oaks, California 91320, USA
    J Neurosci 23:7504-9. 2003
    ..These data show that chronic NSAID treatment can reduce brain Abeta levels, amyloid plaque burden, and microglial activation in an animal model of Alzheimer's disease...
  15. ncbi request reprint Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma
    Thomas Zander
    Department of Neurology, University Bonn, Germany
    J Neurochem 81:1052-60. 2002
    ..Taken together, treatment of glioma cells with PPARgamma agonists may hold therapeutic potential for the treatment of gliomas...

Research Grants2

  1. Microglial Signaling Mechanisms in Alzheimer's Disease
    Gary E Landreth; Fiscal Year: 2010
    ..We propose to definitively test whether oxidative damage observed in an animal model of AD is due to NADPH oxidase action by examination of animals in which the oxidase has been genetically inactivated. ..
  2. LXR and PPARgamma mediated Abeta clearance mechanisms
    Gary E Landreth; Fiscal Year: 2010
    ..We will test if the actions of PPARy on A clearance are secondary to, and reliant upon, LXR function. ..